THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Thursday, March 25, 2021
Vectura expands its investment in dry powder inhaler development and manufacturing capabilities.
FREMONT, CA: Vectura Group, an industry-leading inhalation CDMO, announces the expansion of its dry powder inhaler (DPI) development and manufacturing abilities at its facility in Chippenham, U.K. Investment has been made at the site to deploy a new capsule filler, a capsule blister packer, and a Mikron semi-automated device assembly machine. These improvements will support work with capsule inhaler devices, Vectura’s open inhale close (OIC) device, and the lever-operated multi-dose inhaler (LOMI) device used in Hikma’s generic Advair product, which was approved by the U.S. Food and Drug Administration (FDA) recently.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Work on the project has commenced, and the new potentials are scheduled to be available from Q2 2021. This expansion will massively increase the potentials Vectura has in DPI dosage form development, both unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programs. The new semi-automated device assembly line will assist meet customer demand for Vectura’s blister-based, multi-dose DPI devices, offering increased ability to manufacture up to 1 million devices per year.
With expertise in formulation, such as engineered particle development, DPI device design and development, innovative inhalation analytics, and GMP product and device manufacturing, customers can collaborate with Vectura to advance dry powder programs from early development through all clinical phases of development to small-scale commercialization.
Vectura has specialist knowledge and experience in developing dry powder inhalers, and this investment enables them to fully integrate these disciplines under one roof for pre-clinical, clinical, and commercial programs. The investment in new equipment will complement blister-based platform potentials to provide customers with improved flexibility, alongside other inhalation delivery platforms, to offer patients new inhaled therapies.
Vectura’s Chippenham facility is home to innovate science laboratories, manufacturing suites, and offices where the firm’s differentiated technology and skills are leveraged to develop customers’ inhaled products, from high-quality generics new therapies.
More in News